sign free newsletters genetic engineering allow speedy production pfizer biontech experimental vaccine novel coronavirus 90 percent effective preventing disease covid-19 based initial analysis results large phase iii trial companies report safety concerns arisen far create vaccine researchers genetically engineered sars cov-2 genes captured blueprint embedded blueprint rna molecule solution injected solution bodies trial participants method approach outlined graphic june 2020 issue trial data not submitted peer review publication results hold pfizer biontech manufacture large quantities genetically engineered vaccine quickly mark fischetti senior editor covers aspects sustainability credit nick higgins jen christiansen senior graphics editor 4 hours ago robin lloyd |